Particle Sciences completes manufacture of intravaginal ring

By Dan Stanton

- Last updated on GMT

Particle Sciences completes manufacture of intravaginal ring
Particle Sciences completes manufacture of intravaginal ring
CDMO Particle Sciences has completed the manufacture of an intravaginal delivery device for anti-retrovirals that is designed to prevent the transmission of HIV.

The device is a hollow tube designed to deliver tenofovir disoproxil fumarate (TDF) through the vaginal lining to prevent infection by human immunodeficiency virus (HIV). It has already shown efficacy in primate trials and, now the manufacture of trial supplies is complete, it is poised to begin the next stage of development and enter first-in-human studies. 

Mark Mitchnick, CEO of Particle Sciences, told his company had been selected to provide “manufacturing and quality to the project and has just completed the manufacture of the ring for clinical trials.”

The project is being led by the Translational Prevention Research Center at Albert Einstein College of Medicine and is funded by the National Institutes of Health (NIH), with the ring itself being designed by Patrick Kiser, Associate Professor of Biomedical Engineering at Northwestern University.

“The consortium selected us,”​ Mitchnick added, as “Particle Sciences has a long history with prevention technologies and has manufactured a number of other rings that have gone into clinical trials.”

Furthermore, he said it would be likely the company would be involved in further development of the ring.

Though normally the firm designs its own drug delivery devices, he said in this case the ring is a new design. “Therefore there were atypical processes that had to be scaled to make this venture viable, something PS does very well.”

The ring’s design attracts vaginal fluid into the core of the device, solubilizing some of the drug allowing it to be released, the designer Kiser told our sister publication​ last week.

“Other polymers used in IVR design are not capable of releasing TDF because the drug is not soluble in them,”​ he said, adding: “We use a water swellable elastomer in which the drug TDF has appreciable solubility.”

The device could potentially be used to administer a number of other women’s health drugs and preventative therapies.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers